A Medical Device Daily

AerovectRx (Atlanta), which develops respiratory drug delivery technology, reported that its technology is to be included as part of a multi-party $750,000 contract from the Centers for Disease Control and Prevention (CDC; Atlanta) to develop a new intranasal vaccine delivery platform for influenza.

The objective of the contract is to develop a device and associated disposables to deliver vaccines more efficiently and effectively, while eliminating the pain and hazardous medical waste created by injections. The technology is designed to be used in routine settings like doctors’ offices and pharmacies, and mass immunization efforts in places such as schools, hospitals and public health departments.

The new technology is designed to deliver vaccines intranasally in a comfortable microscopic mist featuring much finer droplets than conventional nasal sprays. It utilizes a vibrating mesh nebulizer with a disposable mesh and medication cartridge.

Although the intranasal flu vaccine is an experimental application, the AerovectRx platform technology has received FDA clearance to market the device for general nebulizer use.

“In addition to influenza immunization, we believe that there are many more immunological and therapeutic applications of our delivery platform including biodefense readiness and treatment of chronic diseases,” said Matthew H.J. Kim, founder and CEO of AerovectRx. “Additional vaccine applications could include smallpox, measles and AIDS, while therapy applications could include treatment for chronic diseases such as asthma and diabetes.”

Creare (Hanover, New Hampshire) is the prime contractor for the Small Business Innovation Research (SBIR) Phase I contract and will develop the intranasal vaccine device and associated disposables. AerovectRx will develop, or jointly develop, the products.

The annual market for respiratory drug delivery is estimated at $12 billion.

Potential targeted therapeutic candidates for the AerovectRx technology include treatments for asthma, cystic fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), diabetes, pain management, and for delivery of vaccines and antiviral drugs.

No Comments